Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via <scp>EGFR</scp> status in circulating tumor <scp>DNA</scp>-Reference-Cited by-同舟云学术

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA

Published:2022-07 Issue:15 Volume:13 Page:2201-2209
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Li Yan¹^ORCID,Xu Ziyi²^ORCID,Wang Shouzheng²^ORCID,Zhu Yixiang²^ORCID,Ma Di³^ORCID,Mu Yuxin⁴^ORCID,Ying Jianming¹^ORCID,Li Junling²^ORCID,Xing Puyuan²^ORCID

Affiliation:

1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

3. Department of Medical Oncology, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine Chinese Academy of Medical Sciences Beijing China

4. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai Medical College Fudan University Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14545

Reference24 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer